The radiopharmaceutical is a positron emission tomography myocardial perfusion imaging agent used in patients with known or suspected coronary artery disease, according to a Feb. 25 news release from GE Healthcare.
Flyrcado received FDA approval Sept. 27, and it is expected to be available to all U.S. cardiac positron emission tomography centers by the end of 2025, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
